Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Orismilast - UNION Therapeutics

Next Previous
Search
Drug Profile

Orismilast - UNION Therapeutics

Alternative Names: IBI-353; LEO32731; LP-0058; UNI-50001; UNI-50002

Latest Information Update: 28 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator LEO Pharma
  • Developer Innovent Biologics; LEO Pharma; UNION Therapeutics
  • Class Anti-inflammatories; Antipsoriatics; Benzodioxoles; Chlorinated hydrocarbons; Fluorinated hydrocarbons; Pyridines; Skin disorder therapies; Small molecules; Spiro compounds
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atopic dermatitis; Hidradenitis suppurativa; Plaque psoriasis; Ulcerative colitis

Most Recent Events

  • 12 Feb 2025 UNION Therapeutics completes an End of Phase II meeting with the US FDA for orismilast development program into phase III trial in Atopic dermatitis, prior to February 2025
  • 28 Sep 2024 No recent reports of development identified for phase-I development in Atopic-dermatitis in Denmark (PO, Tablet)
  • 25 Sep 2024 Efficacy and adverse events data from a phase IIb ADESOS trial in Atopic dermatitis released by UNION therapeutics

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top